Zogenix to Participate in Two Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that members of its management team will participate in fireside chats at two upcoming investor conferences: the Stifel 2021 Virtual Healthcare Conference and Guggenheim Virtual 3rd Annual Neuro/Immunology Conference.

The fireside chats will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.

About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs: one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

CONTACTS:

Zogenix[email protected]

InvestorsBrian Ritchie Managing Director, LifeSci Advisors LLC+1 (212) 915-2578 | [email protected]

MediaTrish McCall, Porter Novelli+1 (805) 390-3279 | [email protected]

You May Also Be Interested In

• Figure Technology Solutions Announces Date for Second Quarter 2026 Results
• Synaptics to Release Fourth Quarter and Full Year Fiscal 2026 Results on August 6, 2026
• Traction Uranium Announces Termination of Option Agreement for the Hearty Bay Project